SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.
Using a topical formula with 5% minoxidil and 0.01% retinoic acid is considered effective, as tretinoin can enhance minoxidil results and improve scalp health.
The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.
A user seeks a minoxidil and tretinoin foam-based product for improving a patchy beard in India. They are unsure about the safety of alcohol-based options for beard use.
Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.
The conversation discusses hair loss, with users suggesting treatments like ketoconazole shampoo, finasteride, and dutasteride. Symptoms like burning and tenderness are mentioned, with recommendations to see a dermatologist for potential scarring alopecia.
Using Tretinoin with Minoxidil may increase Minoxidil's absorption and improve hair growth results. The user is seeking advice on how to apply both treatments effectively.
Cold showers may improve scalp health for some, reducing itchiness and dandruff, but may increase dandruff for others while improving hair texture. Individual experiences with cold showers and scalp health vary.
Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.
Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.
The conversation discusses how to mix pyrilutamide for hair loss treatment, suggesting a mixture of 500mg pyrilutamide with 70% ethanol and 30% propylene glycol, and a potential application dose of 1mL. The user has not personally used pyrilutamide but has researched its preparation and application based on others' experiences.
The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.
Apply minoxidil at least 1-2 hours before bed to ensure it dries and doesn't transfer to the pillow. Foam dries faster than liquid, and using a satin beanie after drying can help prevent transfer.
The conversation discusses various hair loss treatments, including minoxidil, finasteride, latanoprost, tretinoin, dutasteride, and cetirizine, with concerns about effectiveness, cost, and potential side effects. Users express skepticism about the product's price and the combination of multiple compounds.
Hair loss treatment progress with Dut, Min, Keto, needling, and RU/Min/Fin/Dut topical. User noticed improvement, believes RU and needling most effective.
The conversation discusses alternative hair growth treatments to minoxidil, including Stemoxydine, Tretinoin, adenosine, Baicalin, castor oil, Latanoprost/bimatoprost, and Redensyl. Users share their experiences and opinions on the efficacy of these treatments.
The conversation discusses using a 5% Topical Minoxidil with 0.01% Tretinoin serum for hair loss, noting its lack of propylene glycol to avoid itchiness and greasiness. Users share experiences with different Minoxidil formulations and discuss the effectiveness and stability of Tretinoin in various forms.
A 20-year-old is using dutasteride, minoxidil, finasteride with stemoxydine, alfatradiol, ketoconazole shampoo, and dermapen for hair loss and is considering mixing these treatments to save time. They are also contemplating a hair transplant that requires 3500 grafts.
New hair loss treatment called scube3 discussed with mixed opinions. Concerns about pharmaceutical companies preferring repetitive treatments over cures due to profit.
The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.
The user is starting Dutasteride mesotherapy and seeks advice on whether to apply the solution immediately after microneedling or wait 12-24 hours. They couldn't find instructions for first-timers.
The user experienced scalp irritation from a Finasteride and Minoxidil spray and serum. They are considering switching to foam, oral treatments, or another provider.
The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
A 38-year-old woman has been using oral Dutasteride for a year without improvement and is now adding a topical solution containing Minoxidil, Dutasteride, Tretinoin, Ketoconazole, and Hydrocortisone. She is seeking advice on whether switching from oral to topical Dutasteride could prevent hair shedding.
The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.